Q2 2025 Earnings Call Transcript July 31, 2025 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, ...

In the preceding three months, 8 analysts have released ratings for Biogen BIIB -0.98% Get Free Report , presenting a wide ...

US biotech major Biogen (Nasdaq: BIIB) reported a 7% rise in its second quarter revenue Friday, with sales of $2.45 billion.

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

The better-than-expected launch of a rare heart disease drug pushed Alnylam (Nasdaq: ALNY) past the $50 billion market ...

Biotech leaders talked about artificial intelligence and the state's life sciences lead at the Business Journal's summer ...

BofA lowered the firm’s price target on Biogen (BIIB) to $142 from $143 and keeps a Neutral rating on the shares. The firm’s 2025 estimates are ...

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

Blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.

The global digital biomarkers market is set to witness a growth rate of 20% in the next 5 years. Rising prevalence of chronic ...

Revenue (GAAP) surged to $31.7 million, exceeding analysts’ expectations by 88.8% driven by strong ZURZUVAE growth. Net loss (GAAP) narrowed to $49.7 million. This revenue surge, exceeding analysts’ ...